Shanghai Labway Clinical Laboratory Co

Shanghai Labway Clinical Laboratory Co Dividend Coverage

The Dividend Coverage Ratio of Shanghai Labway Clinical Laboratory Co (301060.SZ) as of Nov 4, 2026 is -0.39. In the previous year, Dividend Coverage Ratio was -1.13 — a change of -65.83% (higher).

Dividend Coverage

-0.39

YoY

-65.83%

Last updated:

Dividend Coverage Ratio of Shanghai Labway Clinical Laboratory Co is 2025 -0.39 . Dividend Coverage Ratio of Shanghai Labway Clinical Laboratory Co was 2024 -1.13 . It decreases by -65.83% higher compared to the previous year.

The Shanghai Labway Clinical Laboratory Co Dividend Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend Coverage
Date
Dividend Coverage
Jan 1, 2022
5.14 CNY
Jan 1, 2023
-1.13 CNY
Jan 1, 2025
-0.39 CNY
The Shanghai Labway Clinical Laboratory Co Dividend Coverage history
YEARDividend CoverageYoY
-0.39-65.83%
-1.13-121.97%
5.14—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Labway Clinical Laboratory Co Stock analysis

What does Shanghai Labway Clinical Laboratory Co do? Shanghai Labway Clinical Laboratory Co., Ltd. generates revenue through medical and pathological examination services, including pathological diagnosis, molecular examination, biochemical examination, immune examination, microbial examination, clinical basic examination, and physical and chemical examination. The company also sells in vitro diagnostic instruments, reagents, and related accessories and consumables. Its primary customers are healthcare providers and medical institutions requiring diagnostic services and diagnostic products. The business segments are medical testing services and in vitro diagnostic product sales. The company's medical testing services cater to hospitals and clinics seeking comprehensive diagnostic solutions, while the in vitro diagnostic product sales target healthcare facilities needing equipment and supplies for laboratory operations. These services and products are provided to clients across China, focusing on the healthcare sector's demand for accurate and timely diagnostic capabilities. Shanghai Labway's revenue streams are derived from both service fees for examinations and sales of diagnostic instruments and reagents. The company's offerings align with the growing need for advanced medical diagnostics in China's expanding healthcare market, serving a broad client base within the medical industry. Shanghai Labway Clinical Laboratory Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Labway Clinical Laboratory Co stock

Dividend Coverage Ratio of Shanghai Labway Clinical Laboratory Co is -0.39 in 2025.

Dividend Coverage Ratio of Shanghai Labway Clinical Laboratory Co changed from -1.13 to -0.39, representing a -65.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Shanghai Labway Clinical Laboratory Co since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Shanghai Labway Clinical Laboratory Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Shanghai Labway Clinical Laboratory Co

All Key Metrics — Shanghai Labway Clinical Laboratory Co